Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Ceftolozane-tazobactam versus levofloxacin in urinary tract infection – Authors’ reply

We thank Tom Boyles, Jan Kielstein and Julius Schmidt, and Ciprian Popa and colleagues, for their comments in response to our Article.1 Our trial used a study design that tested intravenous-only therapy, which had both regulatory and clinical precedence. We agree with Boyles that antibiotic stewardship is an important issue and that specific collateral effects can be assessed in such studies, as has been shown in two randomised trials assessing bowel colonisation with resistant Gram-negative bacilli after antimicrobial therapy of intra-abdominal infections with ertapenem versus ceftriaxone-metronidazole.